Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors

(2017) Florencia Cayrol et al.   Nature Communications

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia

(2016) Cristina López et al.   BRITISH JOURNAL OF HAEMATOLOGY

Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance

(2016) S Spinner et al.   LEUKEMIA

Reproducible pharmacogenomic profiling of cancer cell line panels

(2016) Peter M. Haverty et al.   NATURE

Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?

(2015) Marco Herling   EUROPEAN JOURNAL OF HAEMATOLOGY

Genetic characterization of T-PLL reveals two major biologic subgroups andJAK3mutations as prognostic marker

(2015) Anna Stengel et al.   GENES CHROMOSOMES & CANCER

Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1

(2015) L Li et al.   LEUKEMIA

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

(2015) Tea Pemovska et al.   NATURE

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia

(2015) Zainul S. Hasanali et al.   Science Translational Medicine

Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells

(2015) Can Küçük et al.   Nature Communications

Dual-Specificity Phosphatase 4 Regulates STAT5 Protein Stability and Helper T Cell Polarization*

(2015) Wan-Yi Hsiao et al.   PLoS One

Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia

(2014) M. J. Kiel et al.   BLOOD

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma

(2014) Chun-Hao Huang et al.   GENES & DEVELOPMENT

Recurrent mutation ofJAK3in T-cell prolymphocytic leukemia

(2014) Anke K. Bergmann et al.   GENES CHROMOSOMES & CANCER

Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia

(2013) Georg Hopfinger et al.   CANCER

Models for mature T-cell lymphomas—A critical appraisal of experimental systems and their contribution to current T-cell tumorigenic concepts

(2013) Kathrin Warner et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia

(2013) D Bellanger et al.   LEUKEMIA

Mature T-cell Lymphomagenesis Induced by Retroviral Insertional Activation of Janus Kinase 1

(2013) Tim Heinrich et al.   MOLECULAR THERAPY

Inconsistency in large pharmacogenomic studies

(2013) Benjamin Haibe-Kains et al.   NATURE

 -Catenin induces T-cell transformation by promoting genomic instability

(2013) M. Dose et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia

(2013) T. Pemovska et al.   Cancer Discovery

Signaling Network Assessment of Mutations and Copy Number Variations Predict Breast Cancer Subtype-Specific Drug Targets

(2013) Naif Zaman et al.   Cell Reports

T-Cell Receptor Signaling in Peripheral T-Cell Lymphoma – A Review of Patterns of Alterations in a Central Growth Regulatory Pathway

(2013) Kathrin Warner et al.   Current Hematologic Malignancy Reports

How I treat prolymphocytic leukemia

(2012) C. Dearden   BLOOD

Creating and analyzing pathway and protein interaction compendia for modelling signal transduction networks

(2012) Daniel C Kirouac et al.   BMC Systems Biology

SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia

(2012) Hanna L.M. Koskela et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tcl1 interacts with Atm and enhances NF- B activation in hematologic malignancies

(2011) E. Gaudio et al.   BLOOD

DUSP4 deficiency enhances CD25 expression and CD4+T-cell proliferation without impeding T-cell development

(2011) Ching-Yu Huang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

TCL1A gene involvement in T-cell prolymphocytic leukemia in Japanese patients

(2011) Akihiko Yokohama et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium

(2011) W Wiktor-Jedrzejczak et al.   LEUKEMIA

Identification of fusion genes in breast cancer by paired-end RNA-sequencing

(2011) Henrik Edgren et al.   GENOME BIOLOGY

Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study

(2010) Biju Krishnan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

(2010) Wei-Gang Tong et al.   JOURNAL OF CLINICAL ONCOLOGY

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia

(2009) M. Herling et al.   BLOOD

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

(2009) Rong Chen et al.   BLOOD